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INTRODUCTION
It has been shown thatHelicobacter pylori is
highly genetically heterogeneous. A chro-
mosome containing approximately 1,550
genes resulted in a mutant bacterial strain
that adversely affects human health. Previ-
ously, regarded as a treatable infection, H.
pylori is becoming harder to eradicate. The
unique features in H. pylori biology such
as high genetic variability, survival in the
harsh conditions of the stomach, and spe-
cial nitrogen metabolisms have triggered
general research interest on this persistent
infection. Interestingly, the notion“historic
taboo” of sterility of the stomach has been
changed after the successful H. pylori iso-
lation by Marshall and Warren in 1983
(1). It is quite obvious that H. pylori is
emerging as an extraordinary microorgan-
ism, which deserves careful consideration.
Altogether, such particular biological fea-
tures of H. pylori infection led to many
queries in the minds of gastroenterolo-
gists, microbiologists, and even basic biolo-
gists, to spend thousands of hours applying
for grants to study H. pylori (2). Current
knowledge of the H. pylori virulence fac-
tors particularly after the latest findings
in 2012 and 2013 called for new research
on H. pylori and its clinical aspects (3–
5). It is a general belief that certain H.
pylori virutypes should be linked to specific
gastroduodenal diseases, but recent studies
draw an opposite conclusion. Actually, it
is rather the treatment for H. pylori that
is associated with bacterial virulence. The
difficulty observed in H. pylori therapy is
due to unpredictable antibiotic susceptibil-
ity results in various regions, unavailabil-
ity of new effective drugs, and eventually
lack of patient compliance during treat-
ment. In brief, providing a new updated
definition of H. pylori infection represents
a shortcoming in gastrointestinal research.
In this article, we propose realistic views on
H. pylori therapy and virulence according
to the latest findings with focus on a new
definition of diseases caused by H. pylori.
H. PYLORI : OLD BORN BUT NEWLY
RECOGNIZED AS A SUPERBUG
It appears that H. pylori knew what to
do to become a successful human gastric
colonizer and we are just beginning to
understand these mechanisms. Hence, it is
worthwhile to consider new strategies to
win the battle against this rogue microor-
ganism. The H. pylori superbug contains
unique biological features that enable it to
survive safely in harsh environments. While
some scientists insist on beneficiary impact
of H. pylori colonization, others disagree.
Nonetheless, current evidence suggests that
the pathogenicH. pylori phenotype is more
prevalent (6). Altogether, dealing with this
bacterium (superbug ) will be tough and
time consuming. There is no doubt that
improved therapeutic strategies can only be
implemented if we acknowledge H. pylori
as a superbug.
ANTIBIOTIC THERAPY OF H. PYLORI :
DEFEATED STRATEGY?
Undoubtedly, the emergence of resistantH.
pylori strains only few years after its discov-
ery by Warren and Marshall was an under-
estimated event (7–9). Antibiotic therapy
was the first choice against H. pylori due
to the direct association between remission
of digestive diseases and successful bac-
terial eradication. In 1993, due to several
observations of H. pylori resistant cases, a
standard treatment was suggested to pro-
vide a well-established therapeutic regi-
men (10). Standard treatment for H. pylori
infection involves clarithromycin, metron-
idazole, or amoxicillin, in conjunction
with a proton pump inhibitor (PPI). This
approach was originally a promising solu-
tion for reported H. pylori antibiotic resis-
tance (11). Such a complex combination of
drugs to cure the colonized infection has
launched extensive efforts to identify an
ideal simpler successful therapeutic inter-
vention. Unfortunately, a steady increase
in H. pylori resistance to clarithromycin,
amoxicillin, and especially metronidazole
resulted in the diminished use of standard
therapy (12). Nevertheless, Zullo et al. sug-
gested a new“sequential therapy”approach
against reported treatment failures (13).
They proposed using a PPI and amoxicillin
for 5 days followed by a PPI with metron-
idazole and clarithromycin for the next
5 days (13). Despite various recommenda-
tions of suggested treatment regimens, an
achievement of successful eradication was
not possible, and some patients remained
H. pylori positive lifelong. Until today,
whenever a colonized patient is referred
to a gastroenterologist, he/she will be pre-
scribed the common H. pylori therapy, an
old strategy that needs major reconsider-
ation. In other words, globally increasing
antibiotic resistance among H. pylori iso-
lates is the best evidence for the neces-
sity of new therapeutic strategies (14–18).
Even if antibiotic resistance is not a poten-
tial problem, patient compliance can result
in lower efficacy of H. pylori therapeu-
tic regimens. We need to rethink current
treatment strategies regarding this rogue
bacterium. Actually, the frequency of resis-
tant strains has now increased. Currently,
H. pylori antibiotic resistance is much
more problematic than 30 years ago. Con-
versely, the prevalence ofH. pylori infection
compared with 30 years ago is decreasing.
More recently, it has been shown that the
presence of various genetic elements such
as plasmids and phages can explain H.
pylori’s fascinating genetic diversity (19).
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Obviously, such characteristic of H. pylori
infection call for an extraordinary adopted
strategy on how to deal with this bac-
terium, which we may call a “superbug.”
Looking back in the literature can show
that we have never been confronted with
such a complex therapeutic regimen for
any bacterial or viral infection, except for
Mycobacterium tuberculosis and HIV infec-
tion. Considering H. pylori as a super-
bug can be a starting point to investigate
all possible mutations involved in antibi-
otic resistance in greater details. However,
the point mutations in H. pylori genome
are known to be responsible for antibi-
otic resistance. In the near future, new
non-invasive and industrialized tests can
help physicians detect mutations present
in each isolated strain. Accordingly, pre-
scription based on the determined muta-
tional profile can increase the chance of
successful treatment. Therefore, a better
designed antibiotic therapy for H. pylori
will soon become a reality in clinical prac-
tice. During the last decades, several new
virulence factors have been characterized;
however, we have still not identified one
specific H. pylori virulence factor that cov-
ers the whole disease spectrum (20, 21). It
is worthwhile mentioning that new rapid
sequencing technology is providing accu-
rate information about H. pylori genome
and in depth gene structure (4, 22, 23),
validating the present hypothesis about the
association betweenH.pylori virulence fac-
tors and gastroduodenal diseases. As with
H. pylori therapy, scientists are facing a new
challenge in H. pylori virulence factors. At
first glance, we are getting close to discov-
ering the real virulence factor for H. pylori,
but on the other hand, we should pay atten-
tion to the fact that the bacterium harbors a
chromosome with more than 1550 genes of
which most are not functionally character-
ized. Remarkably, our current understand-
ing of H. pylori virulence factors poses a
serious dilemma. There is not enough evi-
dence to use virulence factors as clinically
tools. Further work is required to find a rel-
evant virutype to predict diseases outcome.
Possibly, by the end of 2014, newer detailed
information can ameliorate the current
discussed dilemmas in H. pylori research.
Applying a new definition of H. pylori
infection as a superbug in human stomach,
and placing higher priority on microbe–
human interaction research, can provide
more useful perspectives. Hopefully, these
perspectives will enable researchers to
answer frequently asked questions regard-
ing H. pylori in the near future.
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